Syngeneic murine model for prostate cancer using RM1 cells transfected with gp100

Abstract

Background Prostate cancer (PC) is the most commonly diagnosed solid tumor in men. A major challenge in PC immunotherapy is the lack of an animal model that resembles human adenocarcinoma and allows for manipulation or monitoring of the immune response. Mouse models are needed for preclinical testing of new immunotherapies, whether used alone or in combination with established drugs, and to develop companion biomarkers that can be validated in clinical trials. Methods To develop a syngeneic prostate adenocarcinoma model with a well‐defined tumor antigen, murine RM1 PC cells were transfected with the endogenous mouse melanoma protein, gp100 (RM1‐gp100). Gp100 was attractive because it is a self‐protein and it instantly allowed us to use the large trove of immune research tools developed for melanoma research. A dendritic cell (DC) vaccine was used as model immunotherapy to demonstrate that adoptive immunotherapy against gp100 decreases the growth of RM1‐gp100 but not RM1. Results Expressing gp100 did not change the growth of RM1 cell in vitro or in vivo. The DCs pulsed with RM1‐gp100 could be used to stimulate Pmel‐1 lymphocyte proliferation and activation. Pmel‐1 lymphocytes could be adoptively transferred into C57Bl/6 mice that were treated with DCs pulsed with RM1‐gp100. The resulting Pmel‐1 lymphocytes were monitored to assess the primary cellular immune response and memory response. Conclusion We describe a murine model for prostate adenocarcinoma with a well‐characterized antigen that can be used in an immunologically intact mice to monitor the temporal CD8+ lymphocyte‐mediated antitumor immunity.

Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone

“…LNCaP (RRID:CVCL_0395), CWR22RV1 (RRID:CVCL_1045), PC3 (RRID:CVCL_0035), DU145 (RRID:CVCL_0105), RM1 (RRID:CVCL_B459) and TRAMPC2 cells (ATCC: CRL-2731) were cultured as described previously. 25 , 35 , 36 The stable cell lines used in the study were created using lentiviral transduction. For knockdown of ST6GAL1, previously validated stable cell lines were used.…”

Hypoxia-inducible factor-1α inhibition augments efficacy of programmed cell death 1 antibody in murine prostatic cancer models

“…Nude mice and BALB/c mice, purchased from Cyagen Biosciences Inc. (Suzhou, China), were used to establish the mouse prostate cancer models by transplanting mouse prostate cancer cells subcutaneously. Protocol has been adapted from previous literature [12]. Briefly, 6-8 week old mice were subcutaneously injected with 2 × 10 5 cells.…”

Evaluation the level of human kallikrein-2-hk2, prostate specific antigen and some biochemical parameters in sera of patients with prostate disease

“…Prostate diseases-PC are one of the most common health problems among males, as they directly affect the lifestyle of patients, especially the elderly (1) . PC is the most common type of prostate disease after the age of fifty years (2) ,It is generally slow-growing cancer, as the majority of men with this disease live for many years without symptoms, but it is a life-threatening disease if the disease is not treated in the early stages (3) . The cancer cells in the prostate can metastasize anywhere in the body, most often in the lymph nodes and the bones (4) .…”